Hepatitis B virus infection : definition of a new subgroup of patients eligible for antiviral treatment

Macedo, Guilherme; Lopes, Susana; Araujo, Fernando; Carneiro, Fatima; Veloso, Tavarela
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS90
Academic Journal
An abstract of the article "Hepatitis B Virus Infection : Definition of a New Subgroup of Patients Eligible for Antiviral Treatment," by Guilherme Macedo, Susana Lopes, Fernando Araujo, Fatima Carneiro and Tavarela Veloso is presented.


Related Articles

  • Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. Suzuki, Fumitaka; Tsubota, Akihito; Akuta, Norio; Someya, Takashi; Kobayashi, Masahiro; Suzuki, Yoshiyuki; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Miyakawa, Yuzo; Kumada, Hiromitsu // Journal of Gastroenterology;2002, Vol. 37 Issue 11, p922 

    Background. We aimed to treat patients with chronic hepatitis B on long-term treatment with lamivudine who developed lamivudine-resistant hepatitis B virus (HBV) mutants along with clinical relapses. Methods. Of 217 patients with chronic hepatitis B who had been treated with lamivudine for 1-6...

  • Preface. Kukhanova, Marina // Current Pharmaceutical Design;Mar2000, Vol. 6 Issue 5, p1l 

    Introduces articles about scientific approaches on the rational design and development of antiviral drugs published in the March 2000 issue of the periodical 'Current Pharmaceutical Drug Design.' Design and evaluation of Hepatitis B virus inhibitors; Analysis of the catalytic cycle of HIV-1...

  • Antiviral treatment in chronic infection with hepatitis B virus. Alexander, Graeme; William, Roger // British Medical Journal (Clinical Research Edition);4/5/1986, Vol. 292 Issue 6525, p915 

    Investigates the use of antiviral agents in the treatment of chronic infection with Hepatitis B virus in Great Britain. Risk of patient with hepatitis B to develop chronic liver disease; Relationship between active viral replication and histological activity; Detection by highly sensitive...

  • Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Stockl, Lars; Berting, Andreas; Malkowski, Beate; Foerste, Ramona; Hofschneider, Peter Hans; Hildt, Eberhard // Oncogene;5/1/2003, Vol. 22 Issue 17, p2604 

    The genome of hepatitis B virus (HBV) encodes two transcriptional activators: the HBx protein and the PreS2-activator large surface protein (LHBs). Both proteins trigger activation of c-Raf-1/MEK kinase cascade. In case of HBx this can be mediated by a PKC-independent and Ras-dependent...

  • Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B... Dore, Gregory J.; Cooper, David A.; Barrett, Catherine; Li-Ean Goh; Thakrar, Bharat; Atkins, Mark // Journal of Infectious Diseases;9/1/99, Vol. 180 Issue 3, p607 

    Examines the efficacy and safety of lamivudine in persons coinfected with HIV type 1 and hepatitis B virus (HBV) using a coinfected persons in a randomized, controlled study. Drugs added to lamivudine under the treatment process used in the study; Effect of coinfection with HIV type 1 on HBV...

  • Interaction and Assembly of HBV Structural Proteins: Novel Target Sites of Anti-HBV Agents. Choi, In-Geol; Gyu Yu, Yeon // Infectious Disorders - Drug Targets;Sep2007, Vol. 7 Issue 3, p251 

    Human hepatitis B virus (HBV) causes chronic hepatitis disease which is a major public health problem worldwide. HBV has 4 genes encoding viral DNA polymerase, protein X and two structural proteins, the surface and core proteins. HBV DNA polymerase has been a primary target for the development...

  • Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Lok, Anna S. F.; Ward, John W.; Perrillo, Robert P.; McMahon, Brian J.; Liang, T. Jake // Annals of Internal Medicine;5/15/2012, Vol. 156 Issue 10, p743 

    The article discusses the complications of immunosuppressive therapy. It states that the reactivation of hepatitis B virus (HBV) replication in patients with chronic or past HBV infection is the biggest complication of immunosuppressive therapy. It further states that the screening for HBV and a...

  • Immune Interventional Strategies against Chronic Infection Diseases and Cancers: Present Challenges and Road Map to Solution. Fazle Akbar, S. M.; Mamun-Al-Mahtab // Euroasian Journal of Hepato-Gastroenterology;Jan-Jun2011, Vol. 1 Issue 1, p5 

    The therapeutic efficacy of antiviral therapy against chronic viral infections and anticancer strategy against cancers is not satisfactory. Most of the antiviral drugs cause reduction of viral replication in chronic virus-infected subjects, however, recovery or cure from diseases does not occur...

  • Small interfering RNA Inhibits Hepatitis B virus replication in mice. Giladi, Hilla; Ketzinel-Gilad, Mali; Rivkin, Ludmila; Felig, Yaakov; Nussbaum, Ofer; Galun, Eithan // Molecular Therapy;Nov2003, Vol. 8 Issue 5, p769 

    Current therapies for chronic hepatitis B virus (HBV) infection are limited in their effect on viral gene expression and replication. Recent reports have shown that RNA interference can be induced in mammalian cells by short interfering RNA duplexes (siRNA). Here we studied the effects of an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics